



Cornell University Veterinary Specialists

Canine Clinical Trial



IMHA HANDPRINT Study

Immune-mediated hemolytic anemia (IMHA) is a common disease that affects all breeds of dogs and is associated with significant morbidity and mortality. The destruction of red blood cells (hemolysis) within the blood is caused by complement activation, and is often fatal.

GOALS The purpose of this interventional study is to assess the efficacy of a drug that inhibits canine complement mediated hemolysis. The drug has undergone safety trials and is shown to be well tolerated in dogs. This is a double-blinded randomized controlled trial; dogs will be randomly assigned to receive either the drug or a placebo.

ELIGIBILITY Any dog between the ages of 6 months and 10 years, diagnosed with IMHA based on specific criteria, undergoing care and treatment at Cornell University Veterinary Specialists or the Cornell University Hospital for Animals.

OVERVIEW

In addition to the usual diagnostic testing and treatments for dogs with this disease process, and as specifically deemed warranted for your pet, s/he will:

- Receive either the test drug or a placebo, randomly assigned.
- Have a small amount of additional blood collected daily for specific testing at Cornell.

COMPENSATION The study will cover the costs of daily bloodwork (complete blood count and chemistry profile) for five consecutive days (over \$1,000 value). In addition, patients will receive the drug or the placebo at no cost.

Principal Investigator:

Robert Goggs, BVSc, DACVECC, DECVECC, PhD, MRCVS.
Cornell University Hospital for Animals.
Elisa Mazzaferro, MS, DVM, PhD, DACVECC.
Cornell University Veterinary Specialists

Contact:

If you think your pet may be a candidate, please contact the Emergency & Critical care Department at CUVS: 203.595.2777.

Interested in
participating?